» Articles » PMID: 14633667

Tea Polyphenol (-)-epigallocatechin-3-gallate Inhibits DNA Methyltransferase and Reactivates Methylation-silenced Genes in Cancer Cell Lines

Overview
Journal Cancer Res
Specialty Oncology
Date 2003 Nov 25
PMID 14633667
Citations 370
Authors
Affiliations
Soon will be listed here.
Abstract

Hypermethylation of CpG islands in the promoter regions is an important mechanism to silence the expression of many important genes in cancer. The hypermethylation status is passed to the daughter cells through the methylation of the newly synthesized DNA strand by 5-cytosine DNA methyltransferase (DNMT). We report herein that (-)-epigallocatechin-3-gallate (EGCG), the major polyphenol from green tea, can inhibit DNMT activity and reactivate methylation-silenced genes in cancer cells. With nuclear extracts as the enzyme source and polydeoxyinosine-deoxycytosine as the substrate, EGCG dose-dependently inhibited DNMT activity, showing competitive inhibition with a K(i) of 6.89 microM. Studies with structural analogues of EGCG suggest the importance of D and B ring structures in the inhibitory activity. Molecular modeling studies also support this conclusion, and suggest that EGCG can form hydrogen bonds with Pro(1223), Glu(1265), Cys(1225), Ser(1229), and Arg(1309) in the catalytic pocket of DNMT. Treatment of human esophageal cancer KYSE 510 cells with 5-50 microM of EGCG for 12-144 h caused a concentration- and time-dependent reversal of hypermethylation of p16(INK4a), retinoic acid receptor beta (RARbeta), O(6)-methylguanine methyltransferase (MGMT), and human mutL homologue 1 (hMLH1) genes as determined by the appearance of the unmethylation-specific bands in PCR. This was accompanied by the expression of mRNA of these genes as determined by reverse transcription-PCR. The re-expression of RARbeta and hMLH1 proteins by EGCG was demonstrated by Western blot. Reactivation of some methylation-silenced genes by EGCG was also demonstrated in human colon cancer HT-29 cells, esophageal cancer KYSE 150 cells, and prostate cancer PC3 cells. The results demonstrate for the first time the inhibition of DNA methylation by a commonly consumed dietary constituent and suggest the potential use of EGCG for the prevention or reversal of related gene-silencing in the prevention of carcinogenesis.

Citing Articles

Polyphenol-Based Prevention and Treatment of Cancer Through Epigenetic and Combinatorial Mechanisms.

Singaravelan N, Tollefsbol T Nutrients. 2025; 17(4).

PMID: 40004944 PMC: 11858336. DOI: 10.3390/nu17040616.


Aberrant DNA Methylation in Esophageal Squamous Cell Carcinoma and its Clinical Implications in Systemic Chemotherapy.

Li Z, Chen X, Li Y, Xu Y, Zhou Y Int J Med Sci. 2025; 22(4):1002-1014.

PMID: 39991775 PMC: 11843145. DOI: 10.7150/ijms.109161.


Epigenetic marvels: exploring the landscape of colorectal cancer treatment through cutting-edge epigenetic-based drug strategies.

Tahghighi A, Seyedhashemi E, Mohammadi J, Moradi A, Esmaeili A, Pornour M Clin Epigenetics. 2025; 17(1):34.

PMID: 39987205 PMC: 11847397. DOI: 10.1186/s13148-025-01844-w.


Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential.

Capasso L, De Masi L, Sirignano C, Maresca V, Basile A, Nebbioso A Molecules. 2025; 30(3).

PMID: 39942757 PMC: 11821029. DOI: 10.3390/molecules30030654.


Epigenetic Properties of Compounds Contained in Functional Foods Against Cancer.

Casari G, Romaldi B, Scire A, Minnelli C, Marzioni D, Ferretti G Biomolecules. 2025; 15(1).

PMID: 39858410 PMC: 11762081. DOI: 10.3390/biom15010015.